Efficacy of Opioid-limiting Pain Management Protocol in Men Undergoing Urethroplasty

Sponsor
University of Alabama at Birmingham (Other)
Overall Status
Recruiting
CT.gov ID
NCT03859024
Collaborator
(none)
60
1
2
54.3
1.1

Study Details

Study Description

Brief Summary

The investigator's study aims to see if an enhanced recovery regimen of pain medications before and during surgery will decrease the use and risk of opioid pain medications as well as improve pain control in anterior urethroplasty patients. Participants will be randomized to one of two pain regimens (enhanced recovery regimen vs standard regimen).

Detailed Description

The purpose of this study is to assess the difference in narcotics usage between two different pain management protocols after urethroplasty. Management at the current time varies between giving intraoperative painkillers along with peripheral nerve blocks in some patients, while others do not receive this protocol. In this study, one group will continue the historical standard of care of the hospital, receiving postoperative nonsteroidal anti-inflammatory drugs (NSAIDs) and narcotics for pain control. The other group will utilize a protocol to lower narcotics usage, including acetaminophen, gabapentin, Celebrex, and local anesthetic (bupivacaine) in an attempt to reduce the usage of narcotics postoperatively. Given the heightened concern over narcotic usage by postoperative patients, including the risk of chronic usage by even young patients, the objective will be to assess if using this protocol as a new standard can limit the need for postoperative narcotics prescriptions.

In related urological procedures, bupivacaine injections given before surgeries have been shown to significantly lower pain scores after surgery for patients undergoing penile prosthesis. The University of Alabama at Birmingham has also been using an Enhanced Recovery After Surgery (ERAS) protocol, a multimodal presurgical care pathway designed to achieve early recovery after surgical procedures, for cystectomy and seen reduced narcotic usage among those patients.

This study would potentially help determine a new pain management protocol for urology patients undergoing anterior urethroplasty that is both more effective and less risky.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Efficacy of Opioid-limiting Pain Management Protocol in Men Undergoing Urethroplasty
Actual Study Start Date :
Mar 22, 2019
Anticipated Primary Completion Date :
Oct 1, 2022
Anticipated Study Completion Date :
Oct 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Standard Protocol

Patients will receive the historical standard for pain management, which may include narcotics during and after surgery. Postoperative prescriptions ibuprofen 800 mg, and acetaminophen 1000 mg to be taken on a scheduled basis then as needed. Another prescription for oxycodone will be given to be used only if needed.

Drug: Oxycodone
oxycodone tablet
Other Names:
  • oxycontin
  • Drug: Acetaminophen
    acetaminophen tablet
    Other Names:
  • tylenol
  • Drug: Ibuprofen 800 mg
    ibuprofen tablet
    Other Names:
  • advil, motrin
  • Experimental: Enhanced Recovery Protocol

    A combination regimen of acetaminophen, Celebrex and gabapentin pre-op, with 30 mL of 0.5% bupivacaine and 4 mg of dexamethasone given as a perineal nerve block at the time of urethroplasty surgery. Narcotics will be administered judiciously and ass seen fit by the anesthesia and/or surgical teams. Postoperative prescriptions ibuprofen 800 mg, and acetaminophen 1000 mg to be taken on a scheduled basis then as needed. Another prescription for oxycodone will be given to be used only if needed.

    Drug: Oxycodone
    oxycodone tablet
    Other Names:
  • oxycontin
  • Drug: Acetaminophen
    acetaminophen tablet
    Other Names:
  • tylenol
  • Drug: Gabapentin
    gabapentin tablet
    Other Names:
  • neurontin
  • Drug: celebrex
    Celebrex tablet
    Other Names:
  • celecoxib
  • Drug: Bupivacaine
    bupivacaine injection
    Other Names:
  • marcaine, exparel
  • Drug: Ibuprofen 800 mg
    ibuprofen tablet
    Other Names:
  • advil, motrin
  • Drug: Dexamethasone
    Dexamethasone injection
    Other Names:
  • decadron, ozurdex
  • Outcome Measures

    Primary Outcome Measures

    1. Participant pain control: Numerical Rating Scale (NRS) [3 weeks]

      Self-report via pain score on the Numerical Rating Scale (NRS) for pain, an 11-point scale for patient self-reporting of pain. A rating of 0 equates to no pain, 1-3 equates to mild pain, 4-6 equates to moderate pain, and 7-10 equates to severe pain. Assessment will occur at clinic visit, at pre-op visit, in pre-op holding before surgery, per anesthesia protocol after surgery in recovery and discharge unit, and at postoperative visit

    2. Opioid medication use [3 weeks]

      Amount of opioid medication used, based on return pill count at postoperative visit.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    Male
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Men greater than 18 years of age who are scheduled for anterior urethroplasty surgery
    Exclusion Criteria:
    • Any patient not classified as a II or III on the American Society of Anesthesiologists (ASA) physical status classification system.

    • General anesthesia or neuraxial anesthesia with epidural used as anesthetic techniques

    • Allergy/intolerance to local anesthetic or steroids

    • Pre-existing neurological and/or anatomical deficit that would preclude regional block

    • Coexisting coagulopathy such as hemophilia or von Willebrand Disease

    • BMI greater than 40 or less then 20

    • History of intravenous drug or opioid abuse

    • History of opioid use within a week prior to urethroplasty

    • History of any chronic pain syndrome

    • Posterior urethroplasty

    • Patients with chronic kidney disease

    • Patients allergic to NSAIDs

    • Patients requiring more than one buccal graft harvest

    • Patients with graft urethroplasty with site other than buccal

    • Patients with a history of previous urethroplasty

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Alabama of Birmingham Birmingham Alabama United States 35233

    Sponsors and Collaborators

    • University of Alabama at Birmingham

    Investigators

    • Principal Investigator: John P Selph, MD, University of Alabama at Birmingham

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    John Patrick Selph, MD, Principal Investigator, University of Alabama at Birmingham
    ClinicalTrials.gov Identifier:
    NCT03859024
    Other Study ID Numbers:
    • IRB-300002992
    First Posted:
    Mar 1, 2019
    Last Update Posted:
    Mar 18, 2022
    Last Verified:
    Mar 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by John Patrick Selph, MD, Principal Investigator, University of Alabama at Birmingham
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 18, 2022